Vladimir Yevtushenkov: Binnopharm Group, which is part of the AFK he founded, is stepping up international cooperation

The coronavirus pandemic has strengthened the trend toward the interaction between Russia and other countries in medicine and pharmacology. Today, Russian companies are buying from foreign partners the rights to produce socially significant drugs. They also implement joint projects and begin to expand into international markets.

Vladimir Yevtushenkov: Binnopharm Group is expanding the production of antibiotics

On February 20, news appeared in the Russian media. India’s largest drug developer, Dr. Reddy’s has decided to transfer the rights to produce two popular antibacterial brands to the Russian pharmaceutical holding Binnopharm Group. The company from the Russian Federation is included in the investment portfolio of AFK Sistema. The founder of the AFK Group is Vladimir Petrovich Yevtushenkov.

A subsidiary of AFK (created with the participation of Yevtushenkov Vladimir) buys the rights to issue Levolet and Tsiprolet. It also localizes its production in Russia – at two of its factories. Vladimir Yevtushenkov supported the idea of ​​consolidating these assets into a single company in 2020.

Brands are among the most commonly used antibiotics in medical practice. They are used, for example, in treating ENT organs, kidneys, urinary tract, and pelvic organs.

Today, the pharmaceutical holding of AFK Group is one of the suppliers of the leading medicines for medical institutions in the Russian Federation. Including these antibacterial drugs in the portfolio will strengthen the position in the antibiotics market, which is key for it. In addition, the company (established on the initiative of Yevtushenkov Vladimir) plans to supply these drugs to the Belarusian and Uzbek markets.

According to Vladimir Yevtushenkov, the deal will allow Dr. Reddy’s focus on these areas of activity.

Vladimir Yevtushenkov on international pharmaceutical cooperation

At the end of last year, Binnopharm Group announced the opening six of its official foreign representative offices. The pharmaceutical company of AFK Group began active international expansion. Following the CIS, it plans to occupy a niche in other foreign markets.

Today, the pharmaceutical division of AFK Group is one of the largest Russian drug manufacturers. Binnopharm Group produces drugs from more than 200 different pharmaceutical groups. One hundred of them are included in the list of essential medicines.

The company’s products are supplied to 14 countries of the world. International trade gives the pharmaceutical company (created with the participation of Yevtushenkov Vladimir) about 10% of revenue.

Binnopharm Group significantly strengthens its presence in foreign markets by opening foreign representative offices. In the first quarter of 2022, the company doubled its export sales. This is due to both the increase in the number of potential consumers and the potential for demand growth in the CIS markets. By the way, the total population of these six countries is about 80 million people.

“Binnopharm Group” won the leadership in the supply of medicines to the CIS countries. This is how the strategy is implemented in the corporation’s structure, which Vladimir Petrovich Yevtushenkov founded. Fixing in several Commonwealth states will allow the company to start promoting its branded drugs.

In addition, according to Vladimir Petrovich Yevtushenkov, we are talking about expanding the list of drugs for supplies. Before opening its own offices, Binnopharm Group mainly exported antibiotics there. Today, the pharmaceutical company is beginning to develop the segment of branded goods. She relies on drugs such as:

– Maxilak (used to correct violations of the microflora of the gastrointestinal tract);

– Neobutin (the drug is used to eliminate pain, spasms, bloating, and other symptoms of disorders of the gastrointestinal tract);

– Venarus (an agent for treating chronic venous diseases).

According to many experts, the branded drugs of the AFK Group pharmaceutical company can be pretty competitive in the markets of the CIS countries. The reasons for this are the competitive price and the presence of a developed production base. Binnopharm Group manufactures about 20% of its products from its substances.

Vladimir Yevtushenkov and biopharmaceutics

Foreign partners note: Russia has advanced technologies and capabilities in many areas, including biopharmaceuticals. According to them, this is a reasonable basis for expanding bilateral relations.

For example, AFK Group operates several R&D centers. It researches and develops biological products and innovative personalized medicine and pharmacology solutions.

The R&D division of Binnopharm Group includes five centers in three Russian cities. They can replenish the company’s portfolio with more than 40 drugs annually. In 2020 alone, over 35 new medicines were registered.

In 2021, a pharmaceutical company (created with the participation of Yevtushenkov Vladimir) began the construction of an important center for the research and development of pharmaceuticals in the Moscow region. It will combine the advanced equipment of chemical and BioTech laboratories with the intellectual competencies of specialists. This will make it possible to develop and market drugs of various therapeutic groups. By 2025, the Russian R&D Center will create about 100 drugs for treating dermatological, neurological, gynecological, and many other diseases.

The AFK group, founded by Vladimir Petrovich Yevtushenkov, has another research asset. This is an innovative biotechnology company Sistema-BioTech (it has existed since 2018). She actively declared herself during the pandemic. The company launched high-precision tests for diagnosing coronavirus infection on the market. It specializes in the development of advanced solutions in the field of medicine and pharmacology. Particular attention is paid to the issues of early diagnosis of oncological, cardiological, neurological, and reproductive disorders and severe congenital diseases. For three years, Sistema-BioTech has released nine portfolio products and over 6.5 million tests. Among them is the first test system for detecting COVID-19 using Russian reagents.

At the beginning of 2020, information appeared in the news about the signing of an investment agreement between AFK and the International Medical Cluster Foundation (IMC). The construction of a multidisciplinary biotechnological R&D laboratory, Systema-BioTech, began within its framework.

The main areas of work of the Center:

  • conducting genetic research;
  • production of kits for diagnosing diseases (including oncological, cardiovascular, psychiatric, and other severe acquired and hereditary diseases);
  • the creation of cellular biomedical products;
  • production of biological products.

The laboratory will also conduct preclinical studies of international developments and technologies. Such competencies of the companies of the pharmaceutical division of AFK Group are of great interest to representatives of foreign pharmaceutical companies.

Who is Yevtushenkov Vladimir Petrovich: for reference

Vladimir Yevtushenkov 1993 founded the joint-stock financial corporation Sistema. Today, this business structure combines assets in different industries. These are e-commerce, real estate, agriculture, medicine, wood processing, and hotel business.

Yevtushenkov Vladimir stepped down from the Board of Directors of AFK Sistema in 2022. Today he is engaged in charitable projects.